Skip to Content

Biopsy Reclassification Risk in Prostate Cancer Examined

FRIDAY, Nov. 20, 2020 -- Active surveillance for low-risk prostate cancer is associated with a low risk for cancer spread, according to a study published in the Dec. 1 issue of The Journal of Urology.

Peter E. Lonergan, M.D., from the University of California in San Francisco, and colleagues determined predictors of biopsy reclassification at specific time points among 1,031 men with clinically low-risk prostate cancer prospectively enrolled in active surveillance between 2000 and 2016.

The researchers found that biopsy reclassification was associated with prostate-specific antigen (PSA) density 0.15 or greater (hazard ratio [HR], 3.37), percentage biopsy cores positive (HR, 1.27), and high genomic score (HR, 2.81) at first surveillance biopsy as well as at one to three years, after adjusting for other factors. At three to five years, reclassification was associated with PSA density 0.15 or greater (HR, 2.36) and PSA kinetics (HR, 2.19). A Prostate Imaging Reporting and Data System score of 4 to 5 was not associated with biopsy reclassification at any time point. Overall, at seven years, 99 percent of patients were alive and without metastases.

"In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer," a coauthor said in a statement.

Abstract/Full Text (subscription or payment may be required)

© 2020 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Chilblain-Like Lesions During COVID-19 Tied to Type I Interferonopathy

TUESDAY, Dec. 1, 2020 -- Patients presenting with chilblain-like lesions during the COVID-19 pandemic have histologic and biologic patterns of type I interferonopathy, according...

Risk for SARS-CoV-2 Infection Lower for O, Rh− Blood Groups

TUESDAY, Dec. 1, 2020 -- Type O and rhesus-negative (Rh−) blood groups seem to be associated with a lower risk for severe acute respiratory syndrome coronavirus 2...

Colon Cancer Diagnosed Earlier Under Medicaid Expansion

MONDAY, Nov. 30, 2020 -- For colon cancer patients, Medicaid expansion is associated with earlier diagnosis, enhanced access to treatment, and improved surgical care, according to...